SS Innovations International (NASDAQ:SSII) CEO Srivastava Sudhir Purchases 498,753 Shares

SS Innovations International, Inc. (NASDAQ:SSII) CEO Srivastava Sudhir purchased 498,753 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was acquired at an average price of $4.01 per share, for a total transaction of $1,999,999.53. Following the transaction, the chief executive officer owned 109,851,767 shares of the company’s stock, valued at $440,505,585.67. The trade was a 0.46% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

SS Innovations International Stock Performance

Shares of NASDAQ:SSII opened at $4.42 on Wednesday. The company has a market capitalization of $859.07 million and a PE ratio of -88.40. The stock has a fifty day moving average of $4.82 and a 200-day moving average of $6.05. SS Innovations International, Inc. has a one year low of $3.02 and a one year high of $22.42.

SS Innovations International (NASDAQ:SSII) last issued its earnings results on Tuesday, January 13th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $14.53 million for the quarter. SS Innovations International had a negative return on equity of 34.13% and a negative net margin of 32.10%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SS Innovations International in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Trading of SS Innovations International

A number of hedge funds have recently modified their holdings of SSII. Handelsbanken Fonder AB grew its holdings in shares of SS Innovations International by 9.3% during the fourth quarter. Handelsbanken Fonder AB now owns 120,000 shares of the company’s stock valued at $682,000 after buying an additional 10,198 shares in the last quarter. JNBA Financial Advisors purchased a new stake in SS Innovations International in the 4th quarter worth about $498,000. Inspire Investing LLC boosted its position in SS Innovations International by 124.4% during the 4th quarter. Inspire Investing LLC now owns 82,773 shares of the company’s stock worth $470,000 after acquiring an additional 45,886 shares during the period. Eversept Partners LP purchased a new position in SS Innovations International during the 4th quarter valued at about $428,000. Finally, AlphaCentric Advisors LLC purchased a new position in SS Innovations International during the 4th quarter valued at about $284,000.

Trending Headlines about SS Innovations International

Here are the key news stories impacting SS Innovations International this week:

• Positive Sentiment: CEO Srivastava purchased 498,753 shares (~$2.0M) at ~$4.01, a small increase to his very large holding — insider buying often signals management confidence. SEC filing: Srivastava purchase
• Positive Sentiment: Director Timothy P. Adams bought 300,000 shares (~$1.2M at $3.99), a ~6% increase in his stake — another insider buy reinforcing management’s commitment. SEC filing: Adams purchase
• Positive Sentiment: Vice-Chair Dr. Frederic H. Moll acquired 501,253 shares (~$2.0M at $3.99), increasing his holding — further insider participation. SEC filing: Moll purchase
• Positive Sentiment: SS Innovations completed a private placement raising ~$18.6M (5.77M shares sold) to fund global expansion and working capital; Manipal Global Health Services led the institutional portion and insiders participated. Proceeds support U.S./EU market push while awaiting FDA review of the SSi Mantra. GlobeNewswire: Private placement
• Positive Sentiment: Company released Q4 and full‑year 2025 unaudited results highlighting strong growth in SSi Mantra installations, procedures and revenue — supports the growth narrative as the firm scales device adoption. GlobeNewswire: Q4/FY2025 results
• Neutral Sentiment: Quiver/market data indicates some institutional additions to SSII in recent quarters, which could provide longer‑term support but may not change near‑term volatility. QuiverQuant: Placement/ownership summary
• Negative Sentiment: The private placement included a material share issuance (5.77M shares) and unregistered securities (and warrants issued to a FINRA firm), creating dilution and some liquidity/registration constraints — a common reason for downward pressure. GlobeNewswire: Private placement terms
• Negative Sentiment: SSII’s growth depends on regulatory approvals (FDA 510(k) review expected mid‑2026 and CE marking efforts). Timing and outcome create execution risk that can keep the stock volatile. GlobeNewswire: Regulatory timeline

About SS Innovations International

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015. AVRA Medical Robotics, Inc was founded in 2015 and is based in Orlando, Florida.